{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:29Z","timestamp":1794047489571,"version":"4.8.0"},"reference-count":43,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"3","license":[{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Post-transplant cyclophosphamide (PTCy) has contributed to the success of haploidentical hematopoietic stem cell transplantation (HSCT) and is also used in transplantation from matched donors. However, limited data on the immune reconstitution after this type of immunosuppression is available. We aimed to evaluate immune reconstitution after HSCT from unrelated donors, comparing anti-thymocyte globulin (ATG) and PTCy. Consecutive patients undergoing HSCT from unrelated donors and receiving either ATG or PTCy were prospectively included. Immune reconstitution analyses were performed by flow cytometry pre-transplant and on days 30, 60, 90, and 180 post-transplant. We included 36 patients, 20 in the ATG group and 16 in the PTCy group. In the early post-transplant period (day [d]+30), the ATG group showed a higher number of total lymphocytes, T, B, and natural killer (NK) cells compared to the PTCy group. However, at d+180, the PTCy group exhibited a higher number of B cells. On d+60 and d+90, the ATG group displayed higher number of NK cells CD56dim compared to the PTCy group, while on d+180, the PTCy group showed higher number of CD56-, CD16+, and, NKG2D+ NK cells. Naive CD4+, transition CD4+, and naive CD8+ T cells on d+60 were identified as risk factors for acute graft-versus-host disease grade 2-4, and a higher count of CD4+ memory cells on d+180 was identified as a risk factor for chronic graft-versus-host disease. In the context of unrelated allogeneic transplantation, immunosuppression with PTCy was associated with later B-, T- and NK-cell reconstitution compared to ATG.<\/jats:p>","DOI":"10.3324\/haematol.2024.285921","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T02:43:54Z","timestamp":1726109034000},"page":"640-650","source":"Crossref","is-referenced-by-count":17,"title":["Immune reconstitution dynamics after unrelated allogeneic transplantation with post-transplant cyclophosphamide compared to classical immunosuppression with anti-thymocyte globulin: a prospective cohort study"],"prefix":"10.3324","volume":"110","author":[{"given":"Mariana Nassif","family":"Kerbauy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda Agostini","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo Javier","family":"Arcuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscila Silva","family":"Cunegundes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucila Nassif","family":"Kerbauy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarisse Martins","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreza Alice Feitosa","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinaki P.","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana Cavalheiro","family":"Marti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Hamerschlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"key":"73122","unstructured":"Ratanatharathorn V, Nash RA, Przepiorka D. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998; 92(7):2303-2314."},{"key":"73123","doi-asserted-by":"crossref","unstructured":"Bacigalupo A, Lamparelli T, Barisione G. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant. 2006; 12(5):560-565.","DOI":"10.1016\/j.bbmt.2005.12.034"},{"key":"73124","doi-asserted-by":"crossref","unstructured":"Soiffer RJ, Kim HT, McGuirk J. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. J Clin Oncol. 2017; 35(36):4003-4011.","DOI":"10.1200\/JCO.2017.75.8177"},{"key":"73125","doi-asserted-by":"crossref","unstructured":"Arai Y, Jo T, Matsui H, Kondo T, Takaori-Kondo A. Efficacy of antithymocyte globulin for allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Leuk Lymphoma. 2017; 58(8):1840-1848.","DOI":"10.1080\/10428194.2016.1266624"},{"key":"73126","doi-asserted-by":"crossref","unstructured":"Arcuri LJ, Kerbauy MN, Kerbauy LN, Santos FPS, Ribeiro AAF, Hamerschlak N. ATG in HLA-matched, peripheral blood, hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome: a secondary analysis of a CIBMTR database. Transplant Cell Ther. 2023; 29(1):40.","DOI":"10.1016\/j.jtct.2022.09.010"},{"key":"73127","doi-asserted-by":"crossref","unstructured":"Kanakry JA, Kasamon YL, Gocke CD. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant. 2013; 19(4):602-606.","DOI":"10.1016\/j.bbmt.2013.01.006"},{"key":"73128","doi-asserted-by":"crossref","unstructured":"Ciurea SO, Mulanovich V, Saliba RM. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012; 18(12):1835-1844.","DOI":"10.1016\/j.bbmt.2012.07.003"},{"key":"73129","doi-asserted-by":"crossref","unstructured":"Tischer J, Engel N, Fritsch S. Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings. Ann Hematol. 2015; 94(10):1677-1688.","DOI":"10.1007\/s00277-015-2423-y"},{"key":"73130","doi-asserted-by":"crossref","unstructured":"Moiseev IS, Pirogova OV, Alyanski AL. Graft-versus-host disease prophylaxis in unrelated peripheral blood stem cell transplantation with post-transplantation cyclophosphamide, tacrolimus, and mycophenolate mofetil. Biol Blood Marrow Transplant. 2016; 22(6):1037-1042.","DOI":"10.1016\/j.bbmt.2016.03.004"},{"key":"73131","doi-asserted-by":"crossref","unstructured":"Mehta RS, Saliba RM, Chen J. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. Br J Haematol. 2016; 173(3):444-455.","DOI":"10.1111\/bjh.13977"},{"key":"73132","doi-asserted-by":"crossref","unstructured":"Rashidi A, Slade M, DiPersio JF, Westervelt P, Vij R, Romee R. Post-transplant high-dose cyclophosphamide after HLA-matched vs haploidentical hematopoietic cell transplantation for AML. Bone Marrow Transplant. 2016; 51(12):1561-1564.","DOI":"10.1038\/bmt.2016.217"},{"key":"73133","doi-asserted-by":"crossref","unstructured":"Gooptu M, Romee R, St Martin A. HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. Blood. 2021; 138(3):273-282.","DOI":"10.1182\/blood.2021011281"},{"key":"73134","doi-asserted-by":"crossref","unstructured":"Battipaglia G, Galimard JE, Labopin M. Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2022; 57(4):562-571.","DOI":"10.1038\/s41409-022-01577-x"},{"key":"73135","doi-asserted-by":"crossref","unstructured":"Bola\u00f1os-Meade J, Reshef R, Fraser R. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol. 2019; 6(3):e132-e143.","DOI":"10.1016\/S2352-3026(18)30221-7"},{"key":"73136","doi-asserted-by":"crossref","unstructured":"Luznik L, Pasquini MC, Logan B. Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies. J Clin Oncol. 2022; 40(4):356-368.","DOI":"10.1200\/JCO.21.02293"},{"key":"73137","doi-asserted-by":"crossref","unstructured":"Jurdi NE, Hoover A, O\u2019Leary D. Phase II study of myeloablative 7-8\/8-matched allotransplantation with posttransplantation cyclophosphamide, tacrolimus, and mycophenolate mofetil. Transplant Cell Ther. 2023; 29(9):576.","DOI":"10.1016\/j.jtct.2023.06.008"},{"key":"73138","doi-asserted-by":"crossref","unstructured":"Bola\u00f1os-Meade J, Hamadani M, Wu J. Posttransplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023; 388(25):2338-2348.","DOI":"10.1056\/NEJMoa2215943"},{"key":"73139","doi-asserted-by":"crossref","unstructured":"van den Brink MR, Velardi E, Perales MA. Immune reconstitution following stem cell transplantation. Hematology Am Soc Hematol Educ Program. 2015; 2015:215-219.","DOI":"10.1182\/asheducation-2015.1.215"},{"key":"73140","doi-asserted-by":"crossref","unstructured":"Elfeky R, Lazareva A, Qasim W, Veys P. Immune reconstitution following hematopoietic stem cell transplantation using different stem cell sources. Expert Rev Clin Immunol. 2019; 15(7):735-751.","DOI":"10.1080\/1744666X.2019.1612746"},{"key":"73141","doi-asserted-by":"crossref","unstructured":"Minculescu L, Marquart HV, Friis LS. Early natural killer cell reconstitution predicts overall survival in T cell-replete allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016; 22(12):2187-2193.","DOI":"10.1016\/j.bbmt.2016.09.006"},{"key":"73142","doi-asserted-by":"crossref","unstructured":"Mackall CL, Fleisher TA, Brown MR. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med. 1995; 332(3):143-149.","DOI":"10.1056\/NEJM199501193320303"},{"key":"73143","unstructured":"Kotecha N, Krutzik PO, Irish JM. Web-based analysis and publication of flow cytometry experiments. Curr Protoc Cytom."},{"key":"73144","doi-asserted-by":"crossref","unstructured":"Rambaldi B, Kim HT, Reynolds C. Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. Blood Adv. 2021; 5(2):352-364.","DOI":"10.1182\/bloodadvances.2020003005"},{"key":"73145","doi-asserted-by":"crossref","unstructured":"Goldsmith SR, Abid MB, Auletta JJ. Post-transplant cyclophosphamide (PTCy) is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood. 2021; 137(23):3291-3305.","DOI":"10.1182\/blood.2020009362"},{"key":"73146","doi-asserted-by":"crossref","unstructured":"Nguyen S, Kuentz M, Vernant JP. Involvement of mature donor T cells in the NK cell reconstitution after haploidentical hematopoietic stem-cell transplantation. Leukemia. 2008; 22(2):344-352.","DOI":"10.1038\/sj.leu.2405041"},{"key":"73147","unstructured":"Abrahamsen IW, S\u00f8mme S, Heldal D, Egeland T, Kvale D, Tj\u00f8nnfjord GE. Immune reconstitution after allogeneic stem cell transplantation: the impact of stem cell source and graft-versus-host disease. Haematologica. 2005; 90(1):86-93."},{"key":"73148","doi-asserted-by":"crossref","unstructured":"Russo A, Oliveira G, Berglund S. NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. Blood. 2018; 131(2):247-262.","DOI":"10.1182\/blood-2017-05-780668"},{"key":"73149","doi-asserted-by":"crossref","unstructured":"Nguyen S, Dhedin N, Vernant JP. NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood. 2005; 105(10):4135-4142.","DOI":"10.1182\/blood-2004-10-4113"},{"key":"73150","doi-asserted-by":"crossref","unstructured":"Hu PF, Hultin LE, Hultin P. Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity. J Acquir Immune Defic Syndr Hum Retrovirol. 1995; 10(3):331-340.","DOI":"10.1097\/00042560-199511000-00005"},{"key":"73151","doi-asserted-by":"crossref","unstructured":"Gaddy J, Broxmeyer HE. Cord blood CD16+56- cells with low lytic activity are possible precursors of mature natural killer cells. Cell Immunol. 1997; 180(2):132-142.","DOI":"10.1006\/cimm.1997.1175"},{"key":"73152","doi-asserted-by":"crossref","unstructured":"Cocker ATH, Liu F, Djaoud Z, Guethlein LA, Parham P. CD56-negative NK cells: Frequency in peripheral blood, expansion during HIV-1 infection, functional capacity, and KIR expression. Front Immunol. 2022; 13:992723.","DOI":"10.3389\/fimmu.2022.992723"},{"key":"73153","doi-asserted-by":"crossref","unstructured":"M\u00fcller-Durovic B, Gr\u00e4hlert J, Devine OP, Akbar AN, Hess C. CD56-negative NK cells with impaired effector function expand in CMV and EBV co-infected healthy donors with age. Aging (Albany NY). 2019; 11(2):724-740.","DOI":"10.18632\/aging.101774"},{"key":"73154","doi-asserted-by":"crossref","unstructured":"Kanakry CG, Coffey DG, Towlerton AM. Origin and evolution of the T cell repertoire after post transplantation cyclophosphamide. JCI Insight. 2016; 1(5):e86252.","DOI":"10.1172\/jci.insight.86252"},{"key":"73155","doi-asserted-by":"crossref","unstructured":"Vivier E, Raulet DH, Moretta A. Innate or adaptive immunity? The example of natural killer cells. Science. 2011; 331(6013):44-49.","DOI":"10.1126\/science.1198687"},{"key":"73156","doi-asserted-by":"crossref","unstructured":"Velardi E, Tsai JJ, van den Brink MRM. T cell regeneration after immunological injury. Nat Rev Immunol. 2021; 21(5):277-291.","DOI":"10.1038\/s41577-020-00457-z"},{"key":"73157","unstructured":"Dulude G, Brochu S, Fontaine P. Thymic and extrathymic differentiation and expansion of T lymphocytes following bone marrow transplantation in irradiated recipients. Exp Hematol. 1997; 25(9):992-1004."},{"key":"73158","doi-asserted-by":"crossref","unstructured":"Alhaj Hussen K, Michonneau D, Biajoux V. CD4+CD8+ T-lymphocytes in xenogeneic and human graft-versus-host disease. Front Immunol. 2020; 11:579776.","DOI":"10.3389\/fimmu.2020.579776"},{"key":"73159","doi-asserted-by":"crossref","unstructured":"Hess NJ, Turicek DP, Riendeau J. Inflammatory CD4\/CD8 double-positive human T cells arise from reactive CD8 T cells and are sufficient to mediate GVHD pathology. Sci Adv. 2023; 9(12):eadf0567.","DOI":"10.1126\/sciadv.adf0567"},{"key":"73160","doi-asserted-by":"crossref","unstructured":"Johannisson A, Festin R. Phenotype transition of CD4+ T cells from CD45RA to CD45R0 is accompanied by cell activation and proliferation. Cytometry. 1995; 19(4):343-352.","DOI":"10.1002\/cyto.990190409"},{"key":"73161","doi-asserted-by":"crossref","unstructured":"Dekker L, Sanders E, Lindemans CA, de Koning C, Nierkens S. Naive T cells in graft versus host disease and graft versus leukemia: innocent or guilty?. Front Immunol. 2022; 13:893545.","DOI":"10.3389\/fimmu.2022.893545"},{"key":"73162","doi-asserted-by":"crossref","unstructured":"Chang YJ, Zhao XY, Huo MR, Huang XJ. Expression of CD62L on donor CD4(+) T cells in allografts: correlation with graft-versus-host disease after unmanipulated allogeneic blood and marrow transplantation. J Clin Immunol. 2009; 29(5):696-704.","DOI":"10.1007\/s10875-009-9293-9"},{"key":"73163","unstructured":"Fedele R, Martino M, Garreffa C. The impact of early CD4+ lymphocyte recovery on the outcome of patients who undergo allogeneic bone marrow or peripheral blood stem cell transplantation. Blood Transfus. 2012; 10(2):174-180."},{"key":"73164","doi-asserted-by":"crossref","unstructured":"Petersen SL, Ryder LP, Bj\u00f6rk P. A comparison of T-, B- and NK-cell reconstitution following conventional or nonmyeloablative conditioning and transplantation with bone marrow or peripheral blood stem cells from human leucocyte antigen identical sibling donors. Bone Marrow Transplant. 2003; 32(1):65-72.","DOI":"10.1038\/sj.bmt.1704084"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285921\/77494","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285921\/78103","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11754\/77494","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:18Z","timestamp":1794046038000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.285921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285921","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,12]]}}}